China's Generic Companies Leaning Toward Innovation To Target Global Market: FT China Healthcare And Life Science Summit
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - While China reported a slowdown of its economic growth in the second quarter - 10.3 percent compared to 11.9 percent in the same year-ago quarter - many economists feared China was close to overheating, but the life science industry in China is still hot to global investors, and Chinese generics companies are evolving to become more integrated and innovative, according to speakers from the FT China Healthcare and Life Science Summit held in Shanghai July 13
You may also be interested in...
Tongjitang Pins Loss On Delayed Implementation Of China's Essential Drug List; Proposed Buyout Still Under Review
SHANGHAI - Tongjitang, the first traditional Chinese medicine company listed on the New York Stock Exchange, reported a $694,000 net loss during the second quarter for the year, attributing it to increased sales and marketing expenses for sales infrastructure and its essential drug sales network
Tongjitang Pins Loss On Delayed Implementation Of China's Essential Drug List; Proposed Buyout Still Under Review
SHANGHAI - Tongjitang, the first traditional Chinese medicine company listed on the New York Stock Exchange, reported a $694,000 net loss during the second quarter for the year, attributing it to increased sales and marketing expenses for sales infrastructure and its essential drug sales network
Return Of Anti-commercial Bribery Campaign In China Could Benefit Big Companies And Blacklist Others
SHANGHAI - Last month, China's Ministry of Health released a notice urging local health authorities to crack down on kickbacks to doctors in return for sales of pharmaceutical products under a policy that would ban drug manufacturers from participating in drug tenders in public hospitals for two years if they are blacklisted